Abbott Laboratories
Rank #318Capital ReturnABT · NYSE · Healthcare
Abbott Laboratories (ABT) — Rank #318 by gross profitability (GP/assets 0.23) · ROE 12.5% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0000001800 · all metrics point-in-time as of the filing date.
About
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Show moreShow less
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915.
Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- IL
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- abbott.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-20 | 2024-12-31filed 2025-02-21 | 2023-12-31filed 2024-02-16 | 2022-12-31filed 2023-02-17 |
|---|---|---|---|---|
| Revenue | 44,328.0 | 41,950.0 | 40,109.0 | 43,653.0 |
| Revenue growth (YoY) | 5.7% | 4.6% | -8.1% | 1.3% |
| Cost of revenue | 19,319.0 | 18,706.0 | 17,975.0 | 19,142.0 |
| Gross profit | 25,009.0 | 23,244.0 | 22,134.0 | 24,511.0 |
| Gross margin | 56.4% | 55.4% | 55.2% | 56.1% |
| Selling, general & administrative | 12,332.0 | 11,697.0 | 10,949.0 | 11,248.0 |
| Research & development | 2,942.0 | 2,844.0 | 2,741.0 | 2,888.0 |
| Operating income | 8,053.0 | 6,825.0 | 6,478.0 | 8,362.0 |
| Operating margin | 18.2% | 16.3% | 16.2% | 19.2% |
| Interest income | 308.0 | 344.0 | 385.0 | 183.0 |
| Interest expense | — | — | 637.0 | 558.0 |
| Pre-tax income | 8,466.0 | 7,013.0 | 6,664.0 | 8,306.0 |
| Income tax expense | 1,942.0 | (6,389.0) | 941.0 | 1,373.0 |
| Net income | 6,524.0 | 13,402.0 | 5,723.0 | 6,933.0 |
| Net margin | 14.7% | 31.9% | 14.3% | 15.9% |
| EPS (basic) | $3.73 | $7.67 | $3.28 | $3.94 |
| EPS (diluted) | $3.72 | $7.64 | $3.26 | $3.91 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?